AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10530967
Drug: Levodopa-carbidopa (0.62
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa-carbidopa (0.62 mg/kg of body weight)
Trial: 7721374
Drug: Metronidazole (22.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (22.5 mg/kg/day for 5 days in 3 divided doses)
Trial: 21785963
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy with cultural tailoring intervention
Trial: 21785963
Drug: Brief medication
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief medication management (Control)
Trial: 25790018
Drug: Seven-day week
RxNorm normalized name: Sevenfact
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seven-day week therapy (usual care physiotherapy provided seven-days a week)
Trial: 25790018
Drug: Circuit class
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Circuit class therapy (physiotherapy in group circuit classes in two 90-min sessions, five-days a week)
Trial: 23552182
Drug: DHEA 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA 400 mg
Trial: 21347997
Drug: Traditional herbal
RxNorm normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional herbal medicines
Trial: 20008182
Drug: Novel therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel therapies that increase fetal hemoglobin production, improve red blood cell hydration, increase nitric oxide availability, and possess anti-inflammatory effects
Trial: 15243932
Drug: V‐TT conjugate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: V‐TT conjugate vaccine (n=22)
Trial: 15243932
Drug: Licensed tetanus-diphtheria
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licensed tetanus-diphtheria toxoid vaccine (Td) (n=10)
Trial: 1537478
Drug: Fermented milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fermented milk containing 10(8)/g Lactobacillus acidophilus and 10(7)/g Bifidobacterium sp
Trial: 24347773
Drug: 2 mg/2
RxNorm normalized name: risperidone 2 mg/2 mL ORAL SYRINGE (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/2 ml DEZ
Trial: 21831266
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (gemcitabine 1000 mg/m(2), oxaliplatin 100 mg/m(2)) followed by surgery and adjuvant gemcitabine (1000 mg/m(2) for 6 months)
Trial: 21831266
Drug: Adjuvant gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant gemcitabine (1000 mg/m(2) for 6 months) after surgery
Trial: 17694216
Drug: Polished and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polished and coated with bonding agent
Trial: 11815683
Drug: Psychiatrists with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychiatrists with a greater percentage of patients on psychotropic medications
Trial: 9612620
Drug: Extended neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended neoadjuvant treatment concepts including chemotherapy
Trial: 9612620
Drug: Optimal surgical
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal surgical treatment
Trial: 2491458
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg omeprazole daily
Trial: 2753302
Drug: Colchicine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine (1 mg/day) for 6 months
Trial: 3655305
Drug: Colchicine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine (1 mg/day)
Trial: 31865457
Drug: Sugammadex with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex with hormonal contraception; Counseling provided: 0.7% (1 out of 134 women) had documented counseling on drug-drug interaction.
Trial: 31101037
Drug: Weight gain
RxNorm normalized name: Nutritional Supplement Oral Powder for Suspension [MUSCLE & WEIGHT GAINER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight gain prevention intervention with tailored behavior change goals, daily weighing on a network-connected electronic scale, and responsive weight and goal coaching delivered remotely by health center registered dietitians.
Trial: 19320235
Drug: CLA 2
RxNorm normalized name: Jencycla 28 Day Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CLA 2 g/day for 4 weeks before and 4 days following intranasal HRV inoculation
Trial: 17050768
Drug: Semistructured Interview
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semistructured Interview for Consideration of Ethnic Culture in Therapy Scale (SSICECTS)
Trial: 10694141
Drug: CREATINE (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CREATINE (5 g of Cr, four times per day for 6 d)
Trial: 10694141
Drug: PLACEBO (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLACEBO (same dosage of maltodextrins)
Trial: 3204161
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (conventional treatment modalities)
Trial: 25716971
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg/day for 12 weeks
Trial: 22700526
Drug: Intervention Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention Group (IG) received a month of weekly 4-hour training for nursing home staff.
Trial: 19919298
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of text and graphics presentation format
Trial: 10989321
Drug: Doxazosin (1-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin (1-4 mg/day)
Trial: 9194510
Drug: combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination of hydrochlorothiazide and amiloride
Trial: 9194510
Drug: amlodipine and
RxNorm normalized name: amlodipine and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amlodipine and combined diuretics
Trial: 9194510
Drug: alpha-methyldopa and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha-methyldopa and combination of hydrochlorothiazide and amiloride
Trial: 8363072
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg morphine in saline
Trial: 8363072
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg morphine in saline
Trial: 8363072
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg morphine in 0.25% bupivacaine
Trial: 3929694
Drug: PSK, MMC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSK, MMC and FT combination
Trial: 3929694
Drug: PSK administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PSK administration
Trial: 27129125
Drug: Metformin 500
RxNorm normalized name: metformin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 500 mg
Trial: 16645424
Drug: K-Mg-citrate (42
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K-Mg-citrate (42 mEq K/d and 21 mEq Mg/d)
Trial: 16645424
Drug: K-Mg-citrate
RxNorm normalized name: citric acid / potassium citrate Oral Solution [Cytra-K]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K-Mg-citrate
Trial: 1840065
Drug: Conventional antidepressants
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional antidepressants
Trial: 6974303
Drug: Enpryn, capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enpryn, capsules containing enteric‐coated pellets
Trial: 6974303
Drug: Rhusal, an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhusal, an enteric‐coated tablet
Trial: 6974303
Drug: Enteric‐coated pellet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric‐coated pellet capsules
Trial: 30692123
Drug: MAA868, single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAA868, single subcutaneous doses
Trial: 21545397
Drug: Low-dose valsartan
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose valsartan (10/20 mg)
Trial: 21545397
Drug: Medium-dose valsartan
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Medium-dose valsartan (40/80 mg)
Trial: 21545397
Drug: High-dose valsartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose valsartan (80/160 mg)
Trial: 11353877
Drug: ACE inhibitor
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitor (lisinopril, 20 mg od)
Trial: 17060064
Drug: ACE inhibitor
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitor (lisinopril)
Trial: 9398953
Drug: Intravenous regional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous regional anaesthesia (IVRA)
Trial: 1878535
Drug: Diltiazem 10
RxNorm normalized name: diltiazem 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 10 mg
Trial: 13678108
Drug: Benzocaine gel
RxNorm normalized name: Benzocaine Gel
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benzocaine gel
Trial: 29283679
Drug: Orthokeratology lens
RxNorm normalized name: lens scale pollen extract
DrugBank: Atriplex lentiformis pollen (DB10760)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthokeratology lens (treatment)
Trial: 29283679
Drug: Both eyes
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both eyes (treatment and control)
Trial: 25709399
Drug: AZD3199 via
RxNorm normalized name: Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34)-peptide of parathyroid hormone (Homo sapiens parath
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD3199 via a Spira nebulizer (Turbuhaler; equivalent delivered doses 5‐3200 μg) or Turbuhaler (single delivered doses of 120‐1920 μg or repeated delivered once‐daily doses 240‐1,680 μg)
Trial: 18676275
Drug: Preoperative regional
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative regional intra-arterial chemotherapy (PRAC)
Trial: 16169761
Drug: Inhaled Formoterol
RxNorm normalized name: formoterol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Formoterol 9 microg bid
Trial: 10714479
Drug: High respirable
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High respirable dose formulation at 30 l min(‐1)
Trial: 10714479
Drug: High respirable
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High respirable dose formulation at 60 l min(‐1)
Trial: 10714479
Drug: Low respirable
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low respirable dose formulation at 30 l min(‐1)
Trial: 10714479
Drug: Low respirable
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low respirable dose formulation at 60 l min(‐1)
Trial: 10714479
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of urinary excretion between formulations
Trial: 8774398
Drug: Medium dose
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose subcutaneous heparin (12,500 units twice per day)
Trial: 8774398
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose subcutaneous heparin (5000 units twice per day)
Trial: 9174558
Drug: Aspirin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (300 mg daily)
Trial: 1282178
Drug: Nicorandil (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil (10 or 20 mg b.i.d.)
Trial: 1282178
Drug: Propranolol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (40 or 80 mg t.i.d.)
Trial: 31004969
Drug: Free from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free from Falls Online (FFFO) - eight weekly sessions with instructional and exercise components
Trial: 26031820
Drug: Postoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative treatment for acute cholecystitis
Trial: 24164228
Drug: Low level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low level laser therapy (InGaAlP laser)
Trial: 17024797
Drug: Kanamycin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kanamycin (100 mg vaginal ovules for 6 days)
Trial: 17024797
Drug: Meclocycline (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meclocycline (35 mg vaginal ovules for 6 days)
Trial: 10685667
Drug: IL-2 and
RxNorm normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-2 and IFN-alpha combination
Trial: 8775698
Drug: Postoperative physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative physical therapy plus continuous passive motion (CPM)
Trial: 8775698
Drug: Postoperative physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative physical therapy (Control)
Trial: 6150000
Drug: Guanfacine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanfacine (2 mg)
Trial: 6150000
Drug: RX 781094
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RX 781094 (0.3 mg/kg)
Trial: 24532078
Drug: Tadalafil (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil (20 mg/die for 2 days)
Trial: 21075465
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy for heart failure
Trial: 20397457
Drug: Body acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Body acupuncture plus auricular‐plaster therapy
Trial: 20397457
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Baihui (GV 20)‐through‐Sishencong (EX‐HN1) puncture, auricular‐plaster therapy and moxibustion on the back‐shu points not used)
Trial: 17666604
Drug: Tinidazole 1
RxNorm normalized name: tinidazole 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinidazole 1 g once daily for 5 days
Trial: 17666604
Drug: Tinidazole 2
RxNorm normalized name: tinidazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinidazole 2 g once daily for 2 days
Trial: 12244386
Drug: 0.1 mg/Kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/Kg chlorpromazine intravenously
Trial: 12244386
Drug: Placebo (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (10 ml of saline intravenous injections)
Trial: 9988395
Drug: Oral estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estrogen (E2 valerate, 2 mg/d) plus medroxyprogesterone acetate (5 mg/d) administered during weeks 3, 4, 7, and 8 for 8 weeks
Trial: 9988395
Drug: Transdermal estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal estrogen (50‐microg or 100‐microg E2 patch)
Trial: 7564363
Drug: Remikiren (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remikiren (single oral administration)
Trial: 2197005
Drug: 5% lidocaine
RxNorm normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Healcome Tattoo Numbing Cream 5% Lidocaine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% lidocaine 0.5 mg.kg‐1 in 7.5% glucose (n = 20)
Trial: 2197005
Drug: 5% meperidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% meperidine 0.5 mg.kg‐1 (n = 22)
Trial: 19074663
Drug: Continuous highly
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous highly active antiretroviral therapy (HAART) for 24 months (arm A)
Trial: 19074663
Drug: Intermittent highly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent highly active antiretroviral therapy (HAART) for 24 months (arm B)
Trial: 16705107
Drug: Policosanol 20
RxNorm normalized name: POLICOSANOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Policosanol 20 mg/d
Trial: 16705107
Drug: Policosanol 40
RxNorm normalized name: POLICOSANOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Policosanol 40 mg/d
Trial: 16705107
Drug: Policosanol 80
RxNorm normalized name: POLICOSANOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Policosanol 80 mg/d
Trial: 7545448
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (5 g total)
Trial: 7545448
Drug: Control (neither
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (neither drug nor placebo)
Trial: 3898418
Drug: Pethidine 100
RxNorm normalized name: Pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pethidine 100 mg
Trial: 7000136
Drug: Oral psoralen
RxNorm normalized name: Psoralen
DrugBank: Psoralen (DB18665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral psoralen and long-wave ultraviolet light (treated side)
Trial: 7000136
Drug: Topical psoralen
RxNorm normalized name: Psoralen
DrugBank: Psoralen (DB18665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical psoralen and long-wave ultraviolet light (previously control side)
Trial: 29361199
Drug: Mavrilimumab 100
RxNorm normalized name: Mavrilimumab
DrugBank: Mavrilimumab (DB12534)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mavrilimumab 100 mg every other week plus methotrexate
Trial: 29361199
Drug: Mavrilimumab (30,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mavrilimumab (30, 100, or 150 mg) or placebo every other week plus methotrexate
Trial: 26297124
Drug: Donepezil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (5 mg for 1 month, then 10 mg for the rest of the months, once daily)
Trial: 21050887
Drug: DMB‐SR floating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMB‐SR floating tablets (HPMC K4M 25 mg, sodium bicarbonate 20 mg, hexadecanol 18 mg)
Trial: 21050887
Drug: Conventional DMB‐SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional DMB‐SR tablets
Trial: 16315025
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg conjugated equine estrogen + 2.5 mg medroxyprogesterone acetate (CEE/MPA)
Trial: 16315025
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg 17beta estradiol + 0.5 mg norethindrone acetate (E2/NETA)
Trial: 14570797
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of propofol
Trial: 14570797
Drug: Bolus followed
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus followed by infusion of propofol
Trial: 10195538
Drug: Epidural ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural ropivacaine 2 mg/mL with fentanyl 4 microg/mL (Group R4F)
Trial: 10195538
Drug: Epidural ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural ropivacaine 2 mg/mL alone (Group R)
Trial: 10195538
Drug: Epidural ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural ropivacaine 2 mg/mL with fentanyl 1 microg/mL (Group R1F)
Trial: 10195538
Drug: Epidural ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural ropivacaine 2 mg/mL with fentanyl 2 microg/mL (Group R2F)
Trial: 10195538
Drug: Epidural ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural ropivacaine 2 mg/mL with fentanyl (all doses)
Trial: 7756100
Drug: Physostigmine transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physostigmine transdermal system (PTS)
Trial: 27959941
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: 231299
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg cephradine every 6 h for 7 days
Trial: 231299
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg pivmecillinam every 6 h for 7 days
Trial: 231299
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg cephradine
Trial: 231299
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg pivmecillinam
Trial: 30040135
Drug: Moxifloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (400 mg, single oral dose)
Trial: 27618796
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg intravenous amisulpride
Trial: 22113087
Drug: Org 25935
RxNorm normalized name: ORG-25935
DrugBank: ORG-25935 (DB12220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Org 25935 (glycine transporter-1 inhibitor)
Trial: 19189246
Drug: S. chrysotrichum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S. chrysotrichum herbal medicinal product (Sc-hmp), standardized in 1.89 mg of SC-2, administered as vaginal suppositories daily for 7 nights